PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer

Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Huaqiang, Liu, Jiaqing, Zhang, Yaxiong, Huang, Yan, Shen, Jiayi, Yang, Yunpeng, Fang, Wenfeng, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075870/
https://www.ncbi.nlm.nih.gov/pubmed/32195359
http://dx.doi.org/10.1038/s41698-020-0112-3
_version_ 1783507105153548288
author Zhou, Huaqiang
Liu, Jiaqing
Zhang, Yaxiong
Huang, Yan
Shen, Jiayi
Yang, Yunpeng
Fang, Wenfeng
Zhang, Li
author_facet Zhou, Huaqiang
Liu, Jiaqing
Zhang, Yaxiong
Huang, Yan
Shen, Jiayi
Yang, Yunpeng
Fang, Wenfeng
Zhang, Li
author_sort Zhou, Huaqiang
collection PubMed
description Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its correlation with preliminary response to immunotherapy in non-small cell lung cancer (NSCLC). Our results indicated that PBRM1 mutation was more likely to be a negative predictive biomarker for immunotherapy in NSCLC.
format Online
Article
Text
id pubmed-7075870
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70758702020-03-19 PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer Zhou, Huaqiang Liu, Jiaqing Zhang, Yaxiong Huang, Yan Shen, Jiayi Yang, Yunpeng Fang, Wenfeng Zhang, Li NPJ Precis Oncol Brief Communication Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its correlation with preliminary response to immunotherapy in non-small cell lung cancer (NSCLC). Our results indicated that PBRM1 mutation was more likely to be a negative predictive biomarker for immunotherapy in NSCLC. Nature Publishing Group UK 2020-03-16 /pmc/articles/PMC7075870/ /pubmed/32195359 http://dx.doi.org/10.1038/s41698-020-0112-3 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Brief Communication
Zhou, Huaqiang
Liu, Jiaqing
Zhang, Yaxiong
Huang, Yan
Shen, Jiayi
Yang, Yunpeng
Fang, Wenfeng
Zhang, Li
PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
title PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
title_full PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
title_fullStr PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
title_full_unstemmed PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
title_short PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
title_sort pbrm1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075870/
https://www.ncbi.nlm.nih.gov/pubmed/32195359
http://dx.doi.org/10.1038/s41698-020-0112-3
work_keys_str_mv AT zhouhuaqiang pbrm1mutationandpreliminaryresponsetoimmunecheckpointblockadetreatmentinnonsmallcelllungcancer
AT liujiaqing pbrm1mutationandpreliminaryresponsetoimmunecheckpointblockadetreatmentinnonsmallcelllungcancer
AT zhangyaxiong pbrm1mutationandpreliminaryresponsetoimmunecheckpointblockadetreatmentinnonsmallcelllungcancer
AT huangyan pbrm1mutationandpreliminaryresponsetoimmunecheckpointblockadetreatmentinnonsmallcelllungcancer
AT shenjiayi pbrm1mutationandpreliminaryresponsetoimmunecheckpointblockadetreatmentinnonsmallcelllungcancer
AT yangyunpeng pbrm1mutationandpreliminaryresponsetoimmunecheckpointblockadetreatmentinnonsmallcelllungcancer
AT fangwenfeng pbrm1mutationandpreliminaryresponsetoimmunecheckpointblockadetreatmentinnonsmallcelllungcancer
AT zhangli pbrm1mutationandpreliminaryresponsetoimmunecheckpointblockadetreatmentinnonsmallcelllungcancer

Ejemplares similares